23 related articles for article (PubMed ID: 9840728)
1. Euphorbia grantii Oliv. standardized extract and its fraction ameliorate doxorubicin-induced cardiomyopathy in Ehrlich carcinoma bearing mice.
Saber MM; Radi MH; El-Shiekh RA; Abdel-Sattar E; El-Halawany AM
J Ethnopharmacol; 2024 Mar; 321():117566. PubMed ID: 38081395
[TBL] [Abstract][Full Text] [Related]
2. Chemosensetizing and cardioprotective effects of resveratrol in doxorubicin- treated animals.
Osman AM; Al-Harthi SE; AlArabi OM; Elshal MF; Ramadan WS; Alaama MN; Al-Kreathy HM; Damanhouri ZA; Osman OH
Cancer Cell Int; 2013; 13():52. PubMed ID: 23714221
[TBL] [Abstract][Full Text] [Related]
3. Three-dimensional aspects of formulation excipients in drug discovery: a critical assessment on orphan excipients, matrix effects and drug interactions.
Veeravalli V; Cheruvu HS; Srivastava P; Vamsi Madgula LM
J Pharm Anal; 2020 Dec; 10(6):522-531. PubMed ID: 33425449
[TBL] [Abstract][Full Text] [Related]
4. Nanocrystal dispersion of DK-I-56-1, a poorly soluble pyrazoloquinolinone positive modulator of α6 GABAA receptors: Formulation approach toward improved in vivo performance.
Mitrović JR; Divović B; Knutson DE; Đoković JB; Vulić PJ; Randjelović DV; Dobričić VD; Čalija BR; Cook JM; Savić MM; Savić SD
Eur J Pharm Sci; 2020 Sep; 152():105432. PubMed ID: 32565331
[TBL] [Abstract][Full Text] [Related]
5. Pharmacological effects of formulation vehicles : implications for cancer chemotherapy.
ten Tije AJ; Verweij J; Loos WJ; Sparreboom A
Clin Pharmacokinet; 2003; 42(7):665-85. PubMed ID: 12844327
[TBL] [Abstract][Full Text] [Related]
6. Effect of methylxanthine derivatives on doxorubicin transport and antitumor activity.
Kakuyama A; Sadzuka Y
Curr Drug Metab; 2001 Dec; 2(4):379-95. PubMed ID: 11766989
[TBL] [Abstract][Full Text] [Related]
7. Differential alteration of cisplatin cytotoxicity and myelotoxicity by the paclitaxel vehicle cremophor EL.
Badary OA; Abdel-Naim AB; Khalifa AE; Hamada FM
Naunyn Schmiedebergs Arch Pharmacol; 2000 Mar; 361(3):339-44. PubMed ID: 10731049
[TBL] [Abstract][Full Text] [Related]
8. Thymoquinone protects against doxorubicin-induced cardiotoxicity without compromising its antitumor activity.
al-Shabanah OA; Badary OA; Nagi MN; al-Gharably NM; al-Rikabi AC; al-Bekairi AM
J Exp Clin Cancer Res; 1998 Jun; 17(2):193-8. PubMed ID: 9700580
[TBL] [Abstract][Full Text] [Related]
9. Safety, pharmacokinetics and biodistribution studies of a beta-galactoside prodrug of doxorubicin for improvement of tumor selective chemotherapy.
Devalapally H; Rajan KS; Akkinepally RR; Devarakonda RK
Drug Dev Ind Pharm; 2008 Aug; 34(8):789-95. PubMed ID: 18608462
[TBL] [Abstract][Full Text] [Related]
10. Reversal of resistance against doxorubicin by a newly developed compound, oxalyl bis(N-phenyl)hydroxamic acid in vitro.
Choudhuri SK; Chatterjee A
Anticancer Drugs; 1998 Oct; 9(9):825-32. PubMed ID: 9840730
[TBL] [Abstract][Full Text] [Related]
11. Antarth, a polyherbal preparation protects against the doxorubicin-induced toxicity without compromising its Antineoplastic activity.
Jagetia GC; Reddy TK; Malagi KJ; Nayak BS; Naidu MB; Ravikiran PB; Kamath SU; Shetty PC; Reddy DS
Phytother Res; 2005 Sep; 19(9):772-8. PubMed ID: 16220569
[TBL] [Abstract][Full Text] [Related]
12. Effect of Cremophor EL on the pharmacokinetics, antitumor activity and toxicity of doxorubicin in mice.
Badary OA; Al-Shabanah OA; Al-Gharably NM; Elmazar MM
Anticancer Drugs; 1998 Oct; 9(9):809-15. PubMed ID: 9840728
[TBL] [Abstract][Full Text] [Related]
13. The use of liposomal anticancer agents to determine the roles of drug pharmacodistribution and P-glycoprotein (PGP) blockade in overcoming multidrug resistance (MDR).
Krishna R; Mayer LD
Anticancer Res; 1999; 19(4B):2885-91. PubMed ID: 10652569
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
